Quotient Biodiagnostics

About Quotient Biodiagnostics

AliveDx, formerly known as Quotient Limited, is a commercial-stage diagnostics company that develops, manufactures, and sells products for the global transfusion diagnostics market. The company's history traces back to Alba Bioscience, which was established in the 1940s as part of the Scottish National Blood Transfusion Service and was later privatized in 2007 to form the foundation of Quotient. In April 2014, Quotient Limited held its initial public offering on the NASDAQ.

The company is led by CEO Manuel O. Méndez, who brought over 30 years of experience in the diagnostic and life science markets when he was appointed in April 2021. His background includes senior roles at Quest Diagnostics, QIAGEN, Abbott Laboratories, and Thermo Fisher Scientific.

AliveDx's business is centered on two key product portfolios: Alba and MosaiQ®. The Alba by Quotient™ brand includes a wide range of conventional blood bank reagents and quality control products used by hospitals, donor collection agencies, and independent testing laboratories. The company sells these products directly and through original equipment manufacturer (OEM) partners.

The MosaiQ® platform is a proprietary, automated microarray technology designed to consolidate multiple tests onto a single platform. It performs blood grouping (immunohematology), serological disease screening, and molecular disease screening from a single sample, aiming to increase laboratory efficiency and reduce costs. The business model for MosaiQ® is based on a "razor/razor blade" strategy, involving the placement of instruments and securing long-term agreements for the microarrays used by the system. The company's client base includes hospitals, donor testing laboratories, and OEMs.